Loading…

Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients

Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-06, Vol.9 (6), p.e98715
Main Authors: Ueda, Shigeto, Kuji, Ichiei, Shigekawa, Takashi, Takeuchi, Hideki, Sano, Hiroshi, Hirokawa, Eiko, Shimada, Hiroko, Suzuki, Hiroaki, Oda, Motoki, Osaki, Akihiko, Saeki, Toshiaki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983
cites cdi_FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983
container_end_page
container_issue 6
container_start_page e98715
container_title PloS one
container_volume 9
creator Ueda, Shigeto
Kuji, Ichiei
Shigekawa, Takashi
Takeuchi, Hideki
Sano, Hiroshi
Hirokawa, Eiko
Shimada, Hiroko
Suzuki, Hiroaki
Oda, Motoki
Osaki, Akihiko
Saeki, Toshiaki
description Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or metastatic breast cancer were treated with single-agent bevacizumab followed by addition of weekly paclitaxel. Optical imaging of patient's breasts was performed to measure tumor total hemoglobin concentration (tHb) and oxygen saturation (stO2) at baseline and on days 1, 3, 6, 8, and 13 after the first infusion of bevacizumab. To assess early metabolic response, 2-deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT), 18F-fluoromisonidazole (FMISO)-PET/CT, and magnetic resonance imaging were performed at baseline and after two cycles of the regimen. Seven patients were grouped as responders (n = 4) and nonresponders (n = 3) on the basis of metabolic response measured by FDG-PET/CT. The responders showed remarkable tumor shrinkage and low accumulations of FMISO tracer relative to those of the nonresponders at the completion of two cycles of chemotherapy. Tumors of both groups showed remarkable attenuation of mean tHb as early as day 1 after therapy initiation. The nonresponders had lower baseline stO2 levels compared with adjacent breast tissue stO2 levels along with a pattern of steadily low stO2 levels during the observation window. On the other hand, the responders appeared to sustain high stO2 levels with temporal fluctuation. Low tumor stO2 level after single-agent bevacizumab treatment was characteristic of the nonresponders. Tumor stO2 level could be a predictor of an additional benefit of bevacizumab over that provided by paclitaxel.
doi_str_mv 10.1371/journal.pone.0098715
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1533745735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418707243</galeid><doaj_id>oai_doaj_org_article_8bdf700a2fd14aa0a71e00a9d1d0998d</doaj_id><sourcerecordid>A418707243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983</originalsourceid><addsrcrecordid>eNqNk9uK2zAQhk1p6W63fYPSCgqFXiSVLB9vFpalh8BCoKdbMZbHjoJtuZK8Tfo6fdFOmuySQAvFF7JG3_wz-tFE0XPB50Lm4u3aTm6Abj7aAeecl0Uu0gfRuShlPMtiLh8e_Z9FT7xfc57KIsseR2dxUvI0jtPz6NdyDEZDx0wPrRla1ljHejuYYN1uG6aeAnazbXGAYOzAHHoq6ZFBE9AxQ6jZn9iGecrpcAZEB1bhLWjzc-qhItmusz-wZtWW6W2wwW6MZnqFvQ0rdDBuSYlVDsEHpmHQJD2SLOn4p9GjBjqPzw7rRfT1_bsv1x9nN8sPi-urm5nO0yLMUpEKlFJWlQSspUBe87KUmFeNEE2BBceyzrIMJSSVlAnnEMuYg6wrnqRlIS-il3vdsbNeHfz1SqRS5kmay5SIxZ6oLazV6Mg0t1UWjPoTsK5V4MjPDlVR1U2-K9HUIgHgkFNDHMpa7LoqatK6PFSbqh5rTTd10J2Inp4MZqVae6sSnhRxEpPAq4OAs98n9OEfLR-oFqgrMzSWxHRvvFZXiShynseJJGr-F4q-Gnuj6YU1huInCW9OEogJuAktTN6rxedP_88uv52yr4_YFUIXVt520-6B-VMw2YPaWe8dNvfOCa52A3LnhtoNiDoMCKW9OHb9PuluIuRvDo4P_A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1533745735</pqid></control><display><type>article</type><title>Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients</title><source>Publicly Available Content (ProQuest)</source><source>PubMed</source><creator>Ueda, Shigeto ; Kuji, Ichiei ; Shigekawa, Takashi ; Takeuchi, Hideki ; Sano, Hiroshi ; Hirokawa, Eiko ; Shimada, Hiroko ; Suzuki, Hiroaki ; Oda, Motoki ; Osaki, Akihiko ; Saeki, Toshiaki</creator><contributor>Katz, Elad</contributor><creatorcontrib>Ueda, Shigeto ; Kuji, Ichiei ; Shigekawa, Takashi ; Takeuchi, Hideki ; Sano, Hiroshi ; Hirokawa, Eiko ; Shimada, Hiroko ; Suzuki, Hiroaki ; Oda, Motoki ; Osaki, Akihiko ; Saeki, Toshiaki ; Katz, Elad</creatorcontrib><description>Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or metastatic breast cancer were treated with single-agent bevacizumab followed by addition of weekly paclitaxel. Optical imaging of patient's breasts was performed to measure tumor total hemoglobin concentration (tHb) and oxygen saturation (stO2) at baseline and on days 1, 3, 6, 8, and 13 after the first infusion of bevacizumab. To assess early metabolic response, 2-deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT), 18F-fluoromisonidazole (FMISO)-PET/CT, and magnetic resonance imaging were performed at baseline and after two cycles of the regimen. Seven patients were grouped as responders (n = 4) and nonresponders (n = 3) on the basis of metabolic response measured by FDG-PET/CT. The responders showed remarkable tumor shrinkage and low accumulations of FMISO tracer relative to those of the nonresponders at the completion of two cycles of chemotherapy. Tumors of both groups showed remarkable attenuation of mean tHb as early as day 1 after therapy initiation. The nonresponders had lower baseline stO2 levels compared with adjacent breast tissue stO2 levels along with a pattern of steadily low stO2 levels during the observation window. On the other hand, the responders appeared to sustain high stO2 levels with temporal fluctuation. Low tumor stO2 level after single-agent bevacizumab treatment was characteristic of the nonresponders. Tumor stO2 level could be a predictor of an additional benefit of bevacizumab over that provided by paclitaxel.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0098715</identifier><identifier>PMID: 24905225</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Alzheimer's disease ; Alzheimers disease ; Angiogenesis inhibitors ; Antibodies, Monoclonal, Humanized - pharmacology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Bevacizumab ; Biomarkers ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - physiopathology ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Computed tomography ; Cytotoxicity ; Cytotoxins - pharmacology ; Cytotoxins - therapeutic use ; Dextrose ; Emission analysis ; Female ; Fluorodeoxyglucose F18 ; Glucose ; Hemodynamics - drug effects ; Hemoglobin ; Hemoglobins - metabolism ; Humans ; Imaging techniques ; Immunotherapy ; Infusion ; Laboratories ; Magnetic resonance ; Magnetic resonance imaging ; Mammography ; Medical imaging ; Medicine and Health Sciences ; Metabolic response ; Metabolism ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Multimodal Imaging ; Oncology ; Optical Imaging ; Oxygen ; Oxygen - metabolism ; Oxygen content ; Oxygenation ; Paclitaxel ; Patient monitoring equipment ; Patients ; PET imaging ; Photonics ; Positron emission ; Positron emission tomography ; Reagents ; Saturation ; Shrinkage ; Spectrum analysis ; Targeted cancer therapy ; Tracers (Biology) ; Treatment Outcome ; Tumors ; Vascular endothelial growth factor</subject><ispartof>PloS one, 2014-06, Vol.9 (6), p.e98715</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Ueda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Ueda et al 2014 Ueda et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983</citedby><cites>FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1533745735/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1533745735?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24905225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Katz, Elad</contributor><creatorcontrib>Ueda, Shigeto</creatorcontrib><creatorcontrib>Kuji, Ichiei</creatorcontrib><creatorcontrib>Shigekawa, Takashi</creatorcontrib><creatorcontrib>Takeuchi, Hideki</creatorcontrib><creatorcontrib>Sano, Hiroshi</creatorcontrib><creatorcontrib>Hirokawa, Eiko</creatorcontrib><creatorcontrib>Shimada, Hiroko</creatorcontrib><creatorcontrib>Suzuki, Hiroaki</creatorcontrib><creatorcontrib>Oda, Motoki</creatorcontrib><creatorcontrib>Osaki, Akihiko</creatorcontrib><creatorcontrib>Saeki, Toshiaki</creatorcontrib><title>Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or metastatic breast cancer were treated with single-agent bevacizumab followed by addition of weekly paclitaxel. Optical imaging of patient's breasts was performed to measure tumor total hemoglobin concentration (tHb) and oxygen saturation (stO2) at baseline and on days 1, 3, 6, 8, and 13 after the first infusion of bevacizumab. To assess early metabolic response, 2-deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT), 18F-fluoromisonidazole (FMISO)-PET/CT, and magnetic resonance imaging were performed at baseline and after two cycles of the regimen. Seven patients were grouped as responders (n = 4) and nonresponders (n = 3) on the basis of metabolic response measured by FDG-PET/CT. The responders showed remarkable tumor shrinkage and low accumulations of FMISO tracer relative to those of the nonresponders at the completion of two cycles of chemotherapy. Tumors of both groups showed remarkable attenuation of mean tHb as early as day 1 after therapy initiation. The nonresponders had lower baseline stO2 levels compared with adjacent breast tissue stO2 levels along with a pattern of steadily low stO2 levels during the observation window. On the other hand, the responders appeared to sustain high stO2 levels with temporal fluctuation. Low tumor stO2 level after single-agent bevacizumab treatment was characteristic of the nonresponders. Tumor stO2 level could be a predictor of an additional benefit of bevacizumab over that provided by paclitaxel.</description><subject>Adult</subject><subject>Alzheimer's disease</subject><subject>Alzheimers disease</subject><subject>Angiogenesis inhibitors</subject><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bevacizumab</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Computed tomography</subject><subject>Cytotoxicity</subject><subject>Cytotoxins - pharmacology</subject><subject>Cytotoxins - therapeutic use</subject><subject>Dextrose</subject><subject>Emission analysis</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose</subject><subject>Hemodynamics - drug effects</subject><subject>Hemoglobin</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Imaging techniques</subject><subject>Immunotherapy</subject><subject>Infusion</subject><subject>Laboratories</subject><subject>Magnetic resonance</subject><subject>Magnetic resonance imaging</subject><subject>Mammography</subject><subject>Medical imaging</subject><subject>Medicine and Health Sciences</subject><subject>Metabolic response</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multimodal Imaging</subject><subject>Oncology</subject><subject>Optical Imaging</subject><subject>Oxygen</subject><subject>Oxygen - metabolism</subject><subject>Oxygen content</subject><subject>Oxygenation</subject><subject>Paclitaxel</subject><subject>Patient monitoring equipment</subject><subject>Patients</subject><subject>PET imaging</subject><subject>Photonics</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Reagents</subject><subject>Saturation</subject><subject>Shrinkage</subject><subject>Spectrum analysis</subject><subject>Targeted cancer therapy</subject><subject>Tracers (Biology)</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9uK2zAQhk1p6W63fYPSCgqFXiSVLB9vFpalh8BCoKdbMZbHjoJtuZK8Tfo6fdFOmuySQAvFF7JG3_wz-tFE0XPB50Lm4u3aTm6Abj7aAeecl0Uu0gfRuShlPMtiLh8e_Z9FT7xfc57KIsseR2dxUvI0jtPz6NdyDEZDx0wPrRla1ljHejuYYN1uG6aeAnazbXGAYOzAHHoq6ZFBE9AxQ6jZn9iGecrpcAZEB1bhLWjzc-qhItmusz-wZtWW6W2wwW6MZnqFvQ0rdDBuSYlVDsEHpmHQJD2SLOn4p9GjBjqPzw7rRfT1_bsv1x9nN8sPi-urm5nO0yLMUpEKlFJWlQSspUBe87KUmFeNEE2BBceyzrIMJSSVlAnnEMuYg6wrnqRlIS-il3vdsbNeHfz1SqRS5kmay5SIxZ6oLazV6Mg0t1UWjPoTsK5V4MjPDlVR1U2-K9HUIgHgkFNDHMpa7LoqatK6PFSbqh5rTTd10J2Inp4MZqVae6sSnhRxEpPAq4OAs98n9OEfLR-oFqgrMzSWxHRvvFZXiShynseJJGr-F4q-Gnuj6YU1huInCW9OEogJuAktTN6rxedP_88uv52yr4_YFUIXVt520-6B-VMw2YPaWe8dNvfOCa52A3LnhtoNiDoMCKW9OHb9PuluIuRvDo4P_A</recordid><startdate>20140606</startdate><enddate>20140606</enddate><creator>Ueda, Shigeto</creator><creator>Kuji, Ichiei</creator><creator>Shigekawa, Takashi</creator><creator>Takeuchi, Hideki</creator><creator>Sano, Hiroshi</creator><creator>Hirokawa, Eiko</creator><creator>Shimada, Hiroko</creator><creator>Suzuki, Hiroaki</creator><creator>Oda, Motoki</creator><creator>Osaki, Akihiko</creator><creator>Saeki, Toshiaki</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140606</creationdate><title>Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients</title><author>Ueda, Shigeto ; Kuji, Ichiei ; Shigekawa, Takashi ; Takeuchi, Hideki ; Sano, Hiroshi ; Hirokawa, Eiko ; Shimada, Hiroko ; Suzuki, Hiroaki ; Oda, Motoki ; Osaki, Akihiko ; Saeki, Toshiaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Alzheimer's disease</topic><topic>Alzheimers disease</topic><topic>Angiogenesis inhibitors</topic><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bevacizumab</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Computed tomography</topic><topic>Cytotoxicity</topic><topic>Cytotoxins - pharmacology</topic><topic>Cytotoxins - therapeutic use</topic><topic>Dextrose</topic><topic>Emission analysis</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose</topic><topic>Hemodynamics - drug effects</topic><topic>Hemoglobin</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Imaging techniques</topic><topic>Immunotherapy</topic><topic>Infusion</topic><topic>Laboratories</topic><topic>Magnetic resonance</topic><topic>Magnetic resonance imaging</topic><topic>Mammography</topic><topic>Medical imaging</topic><topic>Medicine and Health Sciences</topic><topic>Metabolic response</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multimodal Imaging</topic><topic>Oncology</topic><topic>Optical Imaging</topic><topic>Oxygen</topic><topic>Oxygen - metabolism</topic><topic>Oxygen content</topic><topic>Oxygenation</topic><topic>Paclitaxel</topic><topic>Patient monitoring equipment</topic><topic>Patients</topic><topic>PET imaging</topic><topic>Photonics</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Reagents</topic><topic>Saturation</topic><topic>Shrinkage</topic><topic>Spectrum analysis</topic><topic>Targeted cancer therapy</topic><topic>Tracers (Biology)</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ueda, Shigeto</creatorcontrib><creatorcontrib>Kuji, Ichiei</creatorcontrib><creatorcontrib>Shigekawa, Takashi</creatorcontrib><creatorcontrib>Takeuchi, Hideki</creatorcontrib><creatorcontrib>Sano, Hiroshi</creatorcontrib><creatorcontrib>Hirokawa, Eiko</creatorcontrib><creatorcontrib>Shimada, Hiroko</creatorcontrib><creatorcontrib>Suzuki, Hiroaki</creatorcontrib><creatorcontrib>Oda, Motoki</creatorcontrib><creatorcontrib>Osaki, Akihiko</creatorcontrib><creatorcontrib>Saeki, Toshiaki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints database</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ueda, Shigeto</au><au>Kuji, Ichiei</au><au>Shigekawa, Takashi</au><au>Takeuchi, Hideki</au><au>Sano, Hiroshi</au><au>Hirokawa, Eiko</au><au>Shimada, Hiroko</au><au>Suzuki, Hiroaki</au><au>Oda, Motoki</au><au>Osaki, Akihiko</au><au>Saeki, Toshiaki</au><au>Katz, Elad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-06-06</date><risdate>2014</risdate><volume>9</volume><issue>6</issue><spage>e98715</spage><pages>e98715-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Optical imaging techniques for measuring tissue hemoglobin concentration have been recently accepted as a way to assess tumor vascularity and oxygenation. We investigated the correlation between early optical response to single-agent bevacizumab and treatment outcome. Seven patients with advanced or metastatic breast cancer were treated with single-agent bevacizumab followed by addition of weekly paclitaxel. Optical imaging of patient's breasts was performed to measure tumor total hemoglobin concentration (tHb) and oxygen saturation (stO2) at baseline and on days 1, 3, 6, 8, and 13 after the first infusion of bevacizumab. To assess early metabolic response, 2-deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT), 18F-fluoromisonidazole (FMISO)-PET/CT, and magnetic resonance imaging were performed at baseline and after two cycles of the regimen. Seven patients were grouped as responders (n = 4) and nonresponders (n = 3) on the basis of metabolic response measured by FDG-PET/CT. The responders showed remarkable tumor shrinkage and low accumulations of FMISO tracer relative to those of the nonresponders at the completion of two cycles of chemotherapy. Tumors of both groups showed remarkable attenuation of mean tHb as early as day 1 after therapy initiation. The nonresponders had lower baseline stO2 levels compared with adjacent breast tissue stO2 levels along with a pattern of steadily low stO2 levels during the observation window. On the other hand, the responders appeared to sustain high stO2 levels with temporal fluctuation. Low tumor stO2 level after single-agent bevacizumab treatment was characteristic of the nonresponders. Tumor stO2 level could be a predictor of an additional benefit of bevacizumab over that provided by paclitaxel.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24905225</pmid><doi>10.1371/journal.pone.0098715</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2014-06, Vol.9 (6), p.e98715
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1533745735
source Publicly Available Content (ProQuest); PubMed
subjects Adult
Alzheimer's disease
Alzheimers disease
Angiogenesis inhibitors
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Bevacizumab
Biomarkers
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - physiopathology
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Computed tomography
Cytotoxicity
Cytotoxins - pharmacology
Cytotoxins - therapeutic use
Dextrose
Emission analysis
Female
Fluorodeoxyglucose F18
Glucose
Hemodynamics - drug effects
Hemoglobin
Hemoglobins - metabolism
Humans
Imaging techniques
Immunotherapy
Infusion
Laboratories
Magnetic resonance
Magnetic resonance imaging
Mammography
Medical imaging
Medicine and Health Sciences
Metabolic response
Metabolism
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Multimodal Imaging
Oncology
Optical Imaging
Oxygen
Oxygen - metabolism
Oxygen content
Oxygenation
Paclitaxel
Patient monitoring equipment
Patients
PET imaging
Photonics
Positron emission
Positron emission tomography
Reagents
Saturation
Shrinkage
Spectrum analysis
Targeted cancer therapy
Tracers (Biology)
Treatment Outcome
Tumors
Vascular endothelial growth factor
title Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A27%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optical%20imaging%20for%20monitoring%20tumor%20oxygenation%20response%20after%20initiation%20of%20single-agent%20bevacizumab%20followed%20by%20cytotoxic%20chemotherapy%20in%20breast%20cancer%20patients&rft.jtitle=PloS%20one&rft.au=Ueda,%20Shigeto&rft.date=2014-06-06&rft.volume=9&rft.issue=6&rft.spage=e98715&rft.pages=e98715-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0098715&rft_dat=%3Cgale_plos_%3EA418707243%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c758t-5151e333bb3aed31e0d0993e7bf11f8e80e9d666e3a4b33400a2320a3db045983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1533745735&rft_id=info:pmid/24905225&rft_galeid=A418707243&rfr_iscdi=true